Ribociclib for Breast Cancer, Metastatic User Reviews (Page 2)
Brand names: Kisqali
Ribociclib has an average rating of 8.6 out of 10 from a total of 24 reviews for the treatment of Breast Cancer, Metastatic. 83% of reviewers reported a positive experience, while 4% reported a negative experience.
Reviews for Ribociclib
- Anonymous
- Taken for 6 months to 1 year
- July 18, 2024
Kisqali (ribociclib) "Very few side effects. Have been able to continue golf, pickleball, bridge, and a nice social life. 600 mg per day for 3 weeks, then one week off."
Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.
Learn more about Breast Cancer, Metastatic
Care guides
More about ribociclib
- Check interactions
- Compare alternatives
- Reviews (30)
- Latest FDA alerts (1)
- Side effects
- Dosage information
- During pregnancy
- Drug class: CDK 4/6 inhibitors
- Breastfeeding
"I have taken ribociclib for less than 10 days and develop a severe infection and very low white cells so I had to stay at hospital for 10 days to clear my infection"